Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study

被引：3

作者：

Andre, T. ^{[1
,2
]}

Berton, D. ^{[3
,4
]}

Oaknin, A. ^{[5
]}

Moreno Garcia, V. ^{[6
]}

Curigliano, G. ^{[7
,8
]}

Trigo, J. ^{[9
]}

Barretina-Ginesta, M-P. ^{[10
]}

Ellard, S. ^{[11
]}

Tinker, A. V. ^{[12
]}

Miller, R. ^{[13
]}

Pikiel, J. ^{[14
]}

Boni, V. ^{[15
]}

Cresta, S. ^{[16
]}

Pothuri, B. ^{[17
]}

Perez, D. Roda ^{[18
]}

Drew, Y. ^{[19
]}

Veneris, J. ^{[20
]}

Im, E. ^{[21
]}

Banerjee, S. ^{[22
]}

机构：

[1] Sorbonne Univ, Med Oncol, Paris, France

[2] St Antoine Hosp, Paris, France

[3] GINECO, Med Oncol Dept, St Herblain, France

[4] Ctr Rene Gauducheau, Inst Cancerol lOuest, St Herblain, France

[5] Vall Hebron Inst Oncol VHIO, Vall DHebron Univ Hosp, Med Oncol, Barcelona, Spain

[6] Fdn Jimenez Diaz Hosp, START Madrid FJD, Clin Res, Madrid, Spain

[7] European Inst Oncol IRCCS, Div Early Drug Dev, IEO, Milan, Italy

[8] Univ Milan, Milan, Italy

[9] Hosp Ramon & Cajal, Med Oncol Dept, Madrid, Spain

[10] Inst Catala Oncol, Med Oncol Serv, Girona, Spain

[11] BC Canc Kelowna, Med Oncol, Vancouver, BC, Canada

[12] BC Canc, Med Oncol, Vancouver, BC, Canada

[13] UCL, St Bartholomews Hosp London, Med Oncol, London, England

[14] Reg Ctr Oncol, Med Oncol, Gdansk, Poland

[15] Hosp Univ HM Sanchinarro, START Madrid CIOCC, Ctr Integral Oncol Clara Campal, Early Drug Dev Unit, Madrid, Spain

[16] IRCCS Ist Nazl Tumori Fdn, Med Oncol, Milan, Italy

[17] NYU Langone Hlth, Laura & Isaac Perlmutter Canc Ctr, Gynecol Oncol Grp GOG, Obstet & Gynecol, New York, NY USA

[18] Univ Hosp, Dept Med Oncol, Valencia, Spain

[19] Newcastle Hosp NHS Fdn Trust, Northern Ctr Canc Care, Med Oncol, Newcastle Upon Tyne, Tyne & Wear, England

[20] GlaxoSmithKline, Oncol Clin Dept, Waltham, MA USA

[21] GlaxoSmithKline, Clin Dev, Waltham, MA USA

[22] Royal Marsden Hosp NHS Fdn Trust, Gynaecol Dept, London, England

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1375

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

991P

引用

页码：S845 / S846

页数：2

共 50 条

[1] TIME COURSE OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) DURING DOSTARLIMAB THERAPY IN THE GARNET TRIAL
Pothuri, Bhavana
Berton, Dominique
Moreno, Victor
Oaknin, Ana
Perez, Jose Manuel Trigo
Curigliano, Giuseppe
Ellard, Susan
Pikiel, Joanna
Banerjee, Susana
Barretina-Ginesta, Maria-Pilar
Miller, Rowan
Tinker, Anna
Jewell, Andrea
Plummer, Ruth
Joly, Florence
Veneris, Jennifer
Duan, Tao
Andre, Thierry
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A398 - A398
[2] MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS WITH SOLID TUMORS TREATED WITH DOSTARLIMAB IN THE GARNET STUDY
Banerjee, Susana
Andre, Thierry
Berton, Dominique
Oaknin, Ana
Moreno, Victor
Trigo, Jose
Curigliano, Giuseppe
Tinker, Anna
Boni, Valentina
Pilar Barretina-Ginesta, Maria
Pikiel, Joanna
Pothuri, Bhavana
Mirza, Mansoor
Panovcova, Petra
Duan, Tao
Dabrowski, Christine
Zografos, Eleftherios
Veneris, Jennifer
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A27 - A28
[3] TIME COURSE OF ADVERSE EVENTS DURING DOSTARLIMAB TREATMENT IN PATIENTS WITH RECURRENT OR ADVANCED ENDOMETRIAL CANCER IN THE GARNET TRIAL
Oaknin, A.
Gilbert, L.
Tinker, A.
Guo, W.
Im, E.
Pothuri, B.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A74 - A74
[4] Management of hepatorenal syndrome and treatment-related adverse events
Peluso, Lorenzo
Savi, Marzia
Coppalini, Giacomo
Veliaj, Deliana
Villari, Nicola
Albano, Giovanni
Petrou, Stephen
Pace, Maria C.
Fiore, Marco
CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (07) : 1155 - 1162
[5] Managing treatment-related adverse events associated with Alk inhibitors
Rothenstein, J. M.
Letarte, N.
CURRENT ONCOLOGY, 2014, 21 (01) : 19 - 26
[6] Contribution of pharmacoepidemiological studies to the evaluation of treatment-related adverse events
Suissa, Samy
JOINT BONE SPINE, 2006, 73 (06) : 627 - 628
[7] UTILITY DECREMENTS ASSOCIATED WITH TREATMENT-RELATED ADVERSE EVENTS IN SCHIZOPHRENIA
Millier, A.
Amri, I
Toumi, M.
VALUE IN HEALTH, 2014, 17 (03) : A219 - A219
[8] Utilities for treatment-related adverse events in type 2 diabetes
Shingler, S.
Fordham, B.
Evans, M.
Schroeder, M.
Thompson, G.
Dewilde, S.
Lloyd, A. J.
JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (01) : 45 - 55
[9] Management of treatment-related adverse events in patients with multiple myeloma
Mateos, Maria-Victoria
CANCER TREATMENT REVIEWS, 2010, 36 : S24 - S32
[10] The time course of adverse events during dostarlimab treatment in mismatch mutation repair deficient and proficient endometrial cancer patients in the GARNET trial
Hanker, L.
Oaknin, A.
Gilbert, L.
Tinker, A.
Guo, W.
Im, E.
Pothuri, B.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 240 - 241

← 1 2 3 4 5 →